.Pharmacolibrary.Drugs.ATC.J.J05AR11 .Pharmacolibrary.Drugs.ATC.J.J05AR11| name: | LamivudineTenofovirDisoproxilAndEfavirenz | |
| ATC code: | J05AR11 | |
| route: | oral | |
| compartments: | 1 | |
| dosage: | 300 | mg |
| volume of distribution: | 1.3 | L |
| clearance: | 22 | L/h |
| other parameters in model implementation | ||
A fixed-dose combination antiretroviral medication containing lamivudine (a nucleoside reverse transcriptase inhibitor), tenofovir disoproxil fumarate (a nucleotide reverse transcriptase inhibitor), and efavirenz (a non-nucleoside reverse transcriptase inhibitor). This combination is used in the treatment of HIV-1 infection and is approved for use as part of antiretroviral therapy (ART) regimens.
Pharmacokinetic parameters reported in healthy adult subjects after single oral administration of the co-formulated fixed-dose tablet.
Bednasz, CJ, et al., & Morse, GD (2019). Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202. Antimicrobial agents and chemotherapy 63(4) –. DOI:10.1128/AAC.01638-18 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30642925